Email not displaying correctly? View content online | Foward to a friend
Latest from GlobalData   June 2018

Spotlight Media Updates

more >
UK based pharma professionals not anticipating staff relocations after Brexit but EU and US colleagues not so sure

In a recent survey of global healthcare professionals into the impact of Brexit on the Pharma industry, most participants working for UK-headquartered companies did not expect staff relocation's because of Brexit.

Takeda chases after its largest deal yet

Takeda’s possible $65B takeover of Shire could be the largest deal value in pharma this year, says GlobalData a leading data and analytics company. This is the Japanese company’s fifth attempt at merging with Shire, clearly highlighting Takeda’s readiness for this move. Notably, this deal is significantly larger than Takeda’s acquisition of Millennium in 2008 (for $8.8B), Nycomed in 2011 (for $13.7B), and Ariad in 2017 (for $5.2B).

Top 25 Global Pharma Companies by Market Cap (end of 2017)

The performance highlights of the Top 25 publicly traded global Pharma companies for the year 2017 have been confirmed in the latest research from GlobalData, a leading data and analytics company. The completed analysis reveals a number of interesting insights. The pharma sector’s 2017 v 2016 year on year performance inevitably created a mixed picture,...

General surgery market is set to reach $21.6bn by 2024

The general surgery market is forecast to grow steadily moving into the next decade. The market was valued at $14.6 bn in 2017 and is expected to reach a value of $21.6 bn in 2024, increasing at a Compound Annual Growth Rate (CAGR) of 5.7%, according to according to GlobalData, a leading data and analytics company.

Late-stage CKD-induced comorbidity therapeutics market to reach $10.5bn by 2026

Sales for chronic kidney disease (CKD)-induced hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) therapeutics were estimated to be $4.2bn across the seven major markets (7MM*) in 2016. This is expected to grow to $10.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 9.5%, according to GlobalData, a leading data and analytics company.

Need for supportive care in oncology will increase during the next decade

The need for effective supportive care in oncology will increase in the next decade as patients continue to live longer and cancer progresses to become more like a chronic disease. This includes the need for chemotherapy-related conditions, as chemotherapy will remain the backbone of cancer therapy for the foreseeable future, observes GlobalData, a leading data and analytics company.

World Cancer Day: What will 2018 mean for cancer research and treatment?

The theme of this year’s World Cancer Day held on 4th February of “We can. I can.” aimed to reinforce the public message that all individuals and groups can play their part in reducing the global burden of cancer. Indeed in recent years many events have involved collaborations between traditional drug developers, cancer treatment professionals and those of varying disciplines. Examples include the IBM Watson supercomputer which is helping physicians make treatment decisions and the development of other databases such as ASCO’s CancerLinQ which assists oncologists in monitoring and analyzing patient data.

Melanoma sales are projected to rise to $5.5bn in 2026

The value of the melanoma market was estimated to be $3.3bn across the seven major markets (7MM*) in 2016. This is expected to grow to $5.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 5.3%, according to GlobalData, a leading data and analytics company.

Global glaucoma market to reach $3.8bn by 2026

The total glaucoma market was estimated to be $2.6bn across the seven major markets (7MM*) in 2016. This is expected to grow to $3.8bn in 2026, at a Compound Annual Growth Rate (CAGR) of 4.1%, according to GlobalData, a leading data and analytics company.

Multiple sclerosis disease-modifying therapies market to reach $25 billion by 2026

Sales for Multiple Sclerosis (MS) disease-modifying therapies (DMTs) were estimated to be $19.1 billion across the seven major markets (7MM*) in 2016. This is expected to grow to $25.3 billion in 2026, at a Compound Annual Growth Rate (CAGR) of 2.9%, according to GlobalData, a leading data and analytics company.

Singapore’s pharmaceutical market value to reach $1.15 billion by 2021

Singapore’s pharmaceutical market is expected to expand from $903 million in 2016 to $1.15 billion by 2021, according to GlobalData, a leading data and analytics company.

Flexion’s Zilretta poised to shakeup knee osteoarthritis marketplace

Flexion Therapeutics recently announced the FDA approval of Zilretta, (triamcinolone acetonide [TA] extended-release injectable suspension) for the treatment of pain associated with moderate-to-severe knee osteoarthritis (OA). This is a segment of the patient population that GlobalData, a leading data and analytics company, expects to significantly drive the value of the market over the next 10 years.

Gilead’s Kite Pharma acquisition leads GlobalData’s Q3 2017 deals analysis

A recent analysis by GlobalData, a leading data and analytics company, identified the top 10 pharma companies by deal value for quarter 3, in 2017, revealed a number of key insights.

The global negative pressure wound therapy market set to reach $1.3bn in 2024

The global negative pressure wound therapy (NPWT) market, valued at $1.2bn in 2017, is expanding at a Compound Annual Growth Rate (CAGR) of 2.1% and is forecast to reach $1.3bn in 2024, according to GlobalData, a leading data and analytics company. Disposable NPWT devices are expected to increase at a CAGR of 8.3% during the forecast period.

Melanoma to significantly increase in the US adult population

The diagnosed incident cases of melanoma of the skin in men and woman, ages 18 years and older in the *7MM, are forecast to increase from 165,651 cases in 2016 to 206,717 cases in 2026, at an Annual Growth Rate (AGR) of 2.48% according to GlobalData, a leading data and analytics company.

Venezuela’s emerging pharmaceutical markets threatened by economic and political turmoil

Venezuela is one of the emerging pharmaceutical markets in South America, with a major dependence on imports. However, economic and political turmoil along with inefficient patent laws and drug pricing policies are major barriers according to GlobalData, a leading data and analytics company.

Non-small cell lung cancer has largest number of clinical trials in Australia and Globally over the last 5 years

A recent analysis of clinical trial activity in Australia by GlobalData, a leading data and analytics company, revealed that 3,199 clinical trials across all diseases and phases took place in the country between January 01, 2012 and December 31, 2016. Non-small cell lung cancer had the largest number of clinical trials overall in Australia, a pattern reflected globally.

New clinical trials of monoclonal antibodies have grown 115% in the last ten years

New clinical trials of monoclonal antibodies (mAb), have grown 115% globally over the ten year period 2007–2016 according to GlobalData, a leading data and analytics company. The most prominent increase, 26%, occurred in 2015.

Crohn’s Disease diagnosed incident cases set to increase in the 7MM to 2026

The burden of diagnosed Crohn’s disease (CD) is expected to grow between 2016 and 2026 in the seven major markets (7MM) *. Epidemiologists from GlobalData, a leading data and analysis company, forecast an increase in the number of diagnosed incident cases, most notably in the US and Japan. The chart below presents the expected changes in the 7MM from 2016 to 2026.

Taiwan’s Pharmaceutical Market Value to Reach $2.44 billion in 2021

The pharmaceutical market in Taiwan is estimated to reach $2.44 billion in 2021, according to GlobalData, a recognized leader in providing business information and analytics.

Indonesian Pharmaceutical Market Value to Reach $10.11 billion by 2021

Indonesia’s pharmaceutical market is the largest market in the Association of Southeast Nations (ASEAN) and is expected to reach $10.11 billion by 2021, according to GlobalData, a recognized leader in providing business information and analytics.

Crohn’s disease market growth to 2026 fuelled by interleukin inhibitor and anti-integrin therapy launches

The global Crohn’s disease (CD) market valued at $9.2 billion in 2016 is set to reach $13.4 billion by 2026, a Compound Annual Growth Rate (CAGR) of 3.8%, across the * 7MM according to GlobalData, a recognized leader in providing business information and analytics.

Alzheimer’s disease market set for double-digit growth with forecast sales of $14.8Bn by 2026

The global Alzheimer’s Disease (AD) market worth $2.9Bn in 2016 is set to reach $14.8Bn, rising at a Compound Annual Growth Rate (CAGR) of 17.5%, across the * 7MM by 2026 according to GlobalData, a recognized leader in providing business information and analytics.

Russia’s Pharmaceutical Market to Reach $36.61 billion by 2021

Russia’s pharmaceutical market is one of the fastest growing in the world and is expected to reach $36.61 billion by 2021, according to GlobalData, a recognized leader in providing business information and analytics.

Osteoarthritis 7MM market set to be worth $3.5 billion by 2026

The Osteoarthritis (OA) market is expected to increase from $1.6 billion in 2016 to $3.5 billion by 2026 in the seven major markets, * 7MM at a compound annual growth rate (CAGR) of 8.1%, according to GlobalData, a recognized leader in providing business information and analytics.

Global migraine market set to be worth $8.7 Billion by 2026

Global migraine sales are expected to grow to $8.7 billion by 2026, at a Compound Annual Growth Rate (CAGR) of 10.3% across the seven major markets * 7MM, according to GlobalData, a recognized leader in providing business information and analytics. The US will continue to dominate the market with a 77% share of total sales by 2026 followed by Germany (5.6%) and Italy (5.2%).

Healthcare-Associated Gram-Negative market to be worth $3.6 billion by 2026

The global marketplace for healthcare-associated infections (HAIs) caused by Gram-negative bacteria across the seven major pharmaceutical markets * (7MM) is projected to exceed $3.6 billion in sales by 2026, at a Compound Annual Growth Rate (CAGR) of 10.8% from 2016–2026, according to GlobalData, a recognized leader in providing business information and analytics.

Sepsis & septic shock market to be worth $5.9 billion by 2026

The sepsis and septic shock space across the seven major pharmaceutical markets (7MM) of the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan is set to grow from $2.8 billion in 2016 to $5.9 billion by 2026, representing a compound annual growth rate (CAGR) of 7.9%, according to GlobalData, a recognized leader in providing business information and analytics.

Nephrology and Urology Devices market growth predictions drive $57 billion investment

The latest report on the Nephrology and Urology Devices market from GlobalData, a recognized leader in providing business information and analytics, has highlighted how an explosion in diabetes and hypertension combined with aging populations is driving investment to meet patient needs. Leading companies in this field, principally from Europe and North America, have invested over $42 billion in mergers and acquisitions and nearly $15 billion in capital raisings over the last 3 years.

Global Clostridium difficile infections market to approach $1.7 billion by 2026

The Clostridium difficile infections (CDIs) space across the seven major markets of the US, France, Germany, Italy, Spain, the UK and Japan, is set to grow from just under $630 million in 2016 to almost $1.7 billion by 2026, representing a compound annual growth rate of 10.2%, according to GlobalData, a recognized leader in providing business information and analytics.

Hemophilia A and B market to welcome newcomers as established companies fall behind

The hemophilia A and B market, which is set to approach $8 billion by 2026, will see a substantial number of newcomers capture market share from established companies, according to GlobalData, a recognized leader in providing business information and analytics.

Asia-Pacific pedicle screw-based dynamic stabilization systems market to surpass $19 million by 2023

The pedicle screw-based dynamic stabilization systems space across the seven major Asia-Pacific (APAC) markets of Australia, China, India, Japan, New Zealand, South Korea and Taiwan, is set to rise from $12.5 million in 2016 to $19.2 million by 2023, representing a compound annual growth rate (CAGR) of 6.3%, according to GlobalData, a recognized leader in providing business information and analytics.

Hemophilia A and B market to approach $8 billion by 2026

The combined market value for hemophilia A and B across the seven major countries of the US, France, Germany, Italy, Spain, the UK and Japan is set to rise from $6.7 billion in 2016 to almost $8.0 billion in 2026, representing a compound annual growth rate of 1.8%, according to GlobalData, a recognized leader in providing business information and analytics.

Asia-Pacific drug delivery devices market set to leave North America behind by 2026

The drug delivery devices market in North America (United States, Canada and Mexico), which comprises approximate 50% of the global market, grew at a compound average growth rate (CAGR) of 2.6% from 2010 to 2016. However, the Asia-Pacific (APAC) region showed a highest growth with a CAGR of 3.4% during the same period, according to GlobalData, a recognized leader in providing business information and analytics.

Brazil’s highly attractive pharmaceutical market to approach $30 billion by 2021

The Brazilian pharmaceutical market is set to grow from $25.3 billion in 2016 to $29.9 billion in 2021, representing a compound annual growth rate of 3.5%, according to GlobalData, a recognized leader in providing business information and analytics.

Singapore’s pharmaceutical market set to break $1 billion mark by 2019

The pharmaceutical market in Singapore is set to rise from $948 million in 2017 to around $1.2 billion in 2021, and will first exceed the $1 billion mark in 2019, according to GlobalData, a recognized leader in providing business information and analytics.

Venous thromboembolism (VTE) market will see strong growth to 2026, hitting $2.85 billion

The venous thromboembolism (VTE) space across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, is set to rise from $1.95 billion in 2016 to around $2.85 billion by 2026, representing a strong compound annual growth rate (CAGR) of 3.87%, according to GlobalData, a recognized leader in providing business information and analytics.

North America elbow replacement market to hit $29.5 million by 2023

The North American elbow replacement market, which covers Canada, Mexico, and the US, is set to grow from $23 million in 2016 to around $29.5 million by 2023, representing a compound annual growth rate (CAGR) of 3.6%, according to GlobalData, a recognized leader in providing business information and analytics.

request a demo

Make better and more timely decisions thanks to our unique data, expert analysis and innovative solutions delivered through a single platform.

Request a demo